Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2025-12-28 @ 3:57 AM
Study NCT ID:
NCT02151656
Status:
COMPLETED
Last Update Posted:
2016-12-16
First Post:
2014-05-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
F17464 in Acute Schizophrenia Trial
Sponsor:
Pierre Fabre Medicament
Organization:
Study Overview
Official Title:
Effects of F17464 in Acute Exacerbation of Schizophrenia
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FAST
Brief Summary:
The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Study design: double-blind, randomized, placebo-controlled, parallel-groups, fixed-dose design, multicentre study.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2013-005451-32 | EUDRACT_NUMBER | None | View |